Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative

Clinical and Applied Thrombosis/Hemostasis

Volumn 22, Issue 3, 2016, Pages 230-238

  Alshaiban, Abdulelah ^a   Muralidharan Chari, Vandhana ^a   Nepo, Anne ^b   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

adhesion molecules; endothelial cells; heparin; ICAM 1; selectin; sickle cell disease; sickle red blood cells; sulfated nonanticoagulant heparin; tinzaparin

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; TINZAPARIN; BIOLOGICAL MARKER; HEPARIN; ICAM1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ERYTHROCYTE ADHESIVENESS; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SICKLE CELL; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; CELL ADHESION; DRUG EFFECTS; ERYTHROCYTE DISORDER; FEMALE; MALE; METABOLISM; PATHOLOGY; SCID MOUSE; SICKLE CELL ANEMIA; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANEMIA, SICKLE CELL; ANIMALS; BIOMARKERS; CELL ADHESION; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; ERYTHROCYTES, ABNORMAL; FEMALE; HEPARIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE; MICE, SCID; P-SELECTIN;

EID: 84958986474     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029614565880     Document Type: Article

References (35)

1. Steinberg MH,. Management of sickle cell disease. N Engl J Med. 1999; 340 (13): 1021-1030.
2. Creary M, Eisen A,. Acknowledging levels of racism in the definition of "difficult". Am J Bioeth. 2013; 13 (4): 16-18.
3. Creary M, Williamson D, Kulkarni R,. Sickle cell disease: current activities, public health implications, and future directions. J Womens Health (Larchmt). 2007; 16 (5): 575-582.
4. Ataga KI, Key NS,. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007: 91-96.
5. Hebbel RP, Eaton JW, Steinberg MH, White JG,. Erythrocyte/endothelial interactions and the vasocclusive severity of sickle cell disease. Prog Clin Biol Res. 1981; 55: 145-162.
6. Kaul DK, Fabry ME, Costantini F, Rubin EM, Nagel RL,. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest. 1995; 96 (6): 2845-2853.
7. Ataga KI, Orringer EP,. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med. 2003; 115 (9): 721-728.
8. Matsui NM, Varki A, Embury SH,. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood. 2002; 100 (10): 3790-3796.
9. Qari MH, Dier U, Mousa SA,. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost. 2012; 18 (2): 195-200.
10. Mousa SA, Qari MH,. Diagnosis and management of sickle cell disorders. Methods Mol Biol. 2010; 663: 291-307.
11. Charneski L, Congdon HB,. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: a review of the literature. Am J Health Syst Pharm. 2010; 67 (11): 895-900.
12. Gupta K, Gupta P, Solovey A, Hebbel RP,. Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochim Biophys Acta. 1999; 1453 (1): 63-73.
13. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A,. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998; 101 (4): 877-889.
14. Chaplin H Jr, Monroe MC, Malecek AC, Morgan LK, Michael J, Murphy WA,. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J. 1989; 66 (9): 574-584.
15. Garcia DA, Baglin TP, Weitz JI, Samama MM,. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2 suppl): e24. S-e43S.
16. Linhardt RJ, Gunay NS,. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999; 25 (suppl 3): 5-16.
17. Hull RD,. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings. Thromb Haemost. 2008; 99 (3): 502-510.
18. Mousa SA, Al Momen A, Al Sayegh F, et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clin Appl Thromb Hemost. 2010; 16 (4): 365-376.
19. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007; 98 (2): 392-396.
20. van Zuuren EJ, Fedorowicz Z,. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Cochrane Database Syst Rev. 2013; 6: CD010155.
21. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A,. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost. 2006; 96 (6): 816-821.
22. Mousa SA, inventor. Oxidized heparin fractions and their use in inhibiting angiogenesis. US patent 8,071,569. December 6, 2011.
23. Sudha T, Phillips P, Kanaan C, Linhardt RJ, Borsig L, Mousa SA,. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model. Clin Exp Metastasis. 2012; 29 (5): 431-439.
24. Yang Y, Koo S, Lin CS, Neu B,. Specific binding of red blood cells to endothelial cells is regulated by nonadsorbing macromolecules. J Biol Chem. 2010; 285 (52): 40489-40495.
25. Setty BN, Betal SG,. Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes. Blood. 2008; 111 (2): 905-914.
26. Niihara Y, Matsui NM, Shen YM, et al. l -Glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord. 2005; 5: 4.
27. Sudha T, Yalcin M, Lin HY, et al. Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett. 2014; 350 (1-2): 25-33.
28. Alyahya R, Sudha T, Racz M, Stain SC, Mousa SA,. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Int. J. Oncol., 2014. Dec. 19 [Epub ahead of print].
29. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW,. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980; 65 (1): 154-160.
30. Wallace PK, Tario JD Jr, Fisher JL, Wallace SS, Ernstoff MS, Muirhead KA,. Tracking antigen-driven responses by flow cytometry: monitoring proliferation by dye dilution. Cytometry A. 2008; 73 (11): 1019-1034.
31. Embury SH, Matsui NM, Ramanujam S, et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood. 2004; 104 (10): 3378-3385.
32. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH,. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001; 98 (6): 1955-1962.
33. Conran N, Fattori A, Saad ST, Costa FF,. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. Am J Hematol. 2004; 76 (4): 343-347.
34. Gbotosho OT, Cytlak UM, Hannemann A, Rees DC, Tewari S, Gibson JS,. Inhibitors of second messenger pathways and Ca-induced exposure of phosphatidylserine in red blood cells of patients with sickle cell disease. Pflugers Arch. 2013; 466 (7): 1477-1485.
35. Shiu YT, Udden MM, McIntire LV,. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood. 2000; 95 (10): 3232-3241.